Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

435.93 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗

February 13, 2026

A sales partner offered a ray of hope that this company couldn't for itself.

Via The Motley Fool

Friday's session: top gainers and losers in the S&P500 index ↗

February 13, 2026

Via Chartmill

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Via MarketMinute

VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase

February 13, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full...

Via StockStory

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance ↗

February 12, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity ↗

February 02, 2026

Via Chartmill

Vertex (VRTX) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Vertex (VRTX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue

February 12, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full...

Via StockStory

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect

February 10, 2026

Via StockStory

Topics Artificial Intelligence World Trade

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case ↗

January 29, 2026

Via Chartmill

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate ↗

January 13, 2026

Via Chartmill

1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell ↗

February 10, 2026

Vertex stock has climbed more than 60% over three years.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Vertex Before Feb. 12? ↗

February 10, 2026

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12

Via The Motley Fool

Topics Intellectual Property

Provident Dumps 490,000 MapleBear Shares Worth $18 Million ↗

February 09, 2026

Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform.

Via The Motley Fool

Topics Regulatory Compliance

Should You Buy Vertex Pharmaceuticals Before Feb. 12? ↗

February 09, 2026

The next 12 months will be important for the drugmaker.

Via The Motley Fool

The Bond Market Is Flashing a Clear Warning About the Fed: 3 Stocks to Buy ↗

February 08, 2026

The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve.

Via The Motley Fool

Topics Bonds Economy Government

2 Top Healthcare Stocks to Buy in February ↗

February 07, 2026

There's a bright future ahead for both, but it's important to be patient.

Via The Motley Fool

Topics World Trade

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Market-Beating Stocks Worth Investigating

February 04, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals ↗

January 29, 2026

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

Via The Motley Fool

1 Healthcare Stock to Consider Right Now and 2 We Brush Off

January 28, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 23, 2026

Issued on behalf of Avant Technologies Inc.

From Equity Insider

Via GlobeNewswire

Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)

January 21, 2026

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its...

Via StockStory

Topics Artificial Intelligence

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

January 20, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

January 19, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals...

Via StockStory

Topics Artificial Intelligence

My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling ↗

January 19, 2026

These stocks are definitely keepers.

Via The Motley Fool

Topics Artificial Intelligence

3 Profitable Stocks with Open Questions

January 15, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

January 14, 2026

Plenty of growth lies ahead for these top healthcare companies.

Via The Motley Fool

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.